

2014

英文論文

1. 2014 Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, **Kudo M**, Ku Y, Sakamoto M, Nakashima M, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan: Impact of histologically confirmed lymph node metastases on the patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey. **Ann Surg** 259:166-170, 2014 (IF=8.569).
2. 2014 Kamata K, Kitano M, **Kudo M**, Sakamoto H, Kadosaka K, Miyata T, Imai H, Maekawa K, Chikugo T, Kumano M, Hyodo T, Murakami T, Chiba Y, Takeyama Y: Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. **Endoscopy** 46: 22-29, 2014 (IF=5.634).
3. 2014 Utsunomiya T, Shimada M, **Kudo M**, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M for the Liver Cancer Study Group of Japan: Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. **Ann Surg** 259:336-345, 2014 (IF=8.569).
4. 2014 Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, **Kudo M**, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW: Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an international expert panel. **Liver Int** 34:174-183, 2014 (IF=4.470).
5. 2014 Kitano M, Sakamoto H, **Kudo M**: Contrast-enhanced

endoscopic ultrasound. **Digest Endosc** 26:79–85, 2014 (IF=2.715).

6. 2014 **Kudo M**: Prediction of incidence risk of hepatocellular carcinoma by ultrasound elastography. **Liver Cancer** 3:1-5, 2014 (IF=0.000).
7. 2014 Kitano K, Kamata K, **Kudo M**: Reply to Kadayifci and brugge. **Endoscopy** 46:358, 2014 (IF=5.634).
8. 2014 Kawanaka M, Nishio K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, **Kudo M**, Yamada G: Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy. **Liver Cancer** 3:41-52, 2014 (IF=0.000).
9. 2014 Minami Y, Yagyu Y, Murakami T, **Kudo M**: Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma using Three-Dimensional Cone-Beam CT Angiography. **Liver Cancer** 3:53-61, 2014 (IF=0.000).
10. 2014 Minami Y, Nishida N, **Kudo M**: Therapeutic Response Assessment of RFA for HCC: Contrast-enhanced US, CT and MRI. **World J Gastroenterol** 20:4160-4166, 2014 (IF=2.787).
11. 2014 Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, **Kudo M**: Relevance of the core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a± ribavirin for chronic hepatitis C of genotype 1b: A multicenter randomized trial, ReGIT-J study. **J Gastroenterol** 49:492-501, 2014 (IF=4.414).
12. 2014 Hatanaka K, Minami Y, **Kudo M**, Inoue T, Chung H, Haji S: The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US. **J Clin Ultrasound** 42:1-8, 2014

(IF=0.862).

13. 2014 Lencioni R, **Kudo M**, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. **Int J Clin Pract** 68:609-617, 2014 (IF=2.226).
14. 2014 **Kudo M**, Arizumi T, Ueshima K: ART score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma. **Hepatology** 59:2424-2425, 2014 (IF=11.711).
15. 2014 **Kudo M**: Recent advances in Bioinformatics reveal the molecular heterogeneity of hepatocellular carcinoma. **Liver Cancer** 3:68-70, 2014 (IF=0.000).
16. 2014 Togashi Y, Sakamoto H, Hayashi H, Terashima M, Velasco Ma, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, **Kudo M**, Nishio K: Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. **Mol Cancer** 13:126-136, 2014 (IF=5.888).
17. 2014 Zhu AX, **Kudo M**, Assenat E, Cattani S, Kang YK, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen CL, Dorval E, Radosavljevic MPR, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. **J Am Med Assoc (JAMA)** 312:57-67, 2014 (IF=37.684).
18. 2014 Ikeda N, Imanishi H, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Siato M, Iijima H, Iimuro Y, Fujimoto J, Yamamoto S, Hirota S, **Kudo M**, Arii S, Nishiguchi S: Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease

in patients with low platelet count. **Hepato Res** 44:829-836, 2014 (IF=2.208).

19. 2014 Kim SR, Kondo F, Otono Y, Imoto S, Ando K, Hirakawa M, Fukuda K, Sakaki M, Kim SK, Komaki T, Tsuchida S, Kobayashi S, Matsuoka T, **Kudo M**: Serum amyloid A and C-reactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosis. **Hepatol Res** 44:584-590, 2014 (IF=2.208).
20. 2014 Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, **Kudo M**, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M, for the Liver Cancer Study Group of Japan: Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1,160 cases from a nationwide survey. **Ann Surg** 259:532-542, 2014 (IF=8.569).
21. 2014 Kitano M, Kamata K, Kudo M: Endoscopic ultrasonography-guided gallbladder drainage procedures: is the glass half-full or half-empty? **Digest Endosc** 26:636-637, 2014 (IF=2.715).
22. 2014 Ogawa K, Fukunaga K, Takeuchi T, Kawagishi N, Ubara Y, **Kudo M**, Ohkohchi N: Current treatment status of polycystic liver disease in Japan. **Hepatol Res** 44:1110-1118, 2014 (IF=2.208).
23. 2014 **Kudo M**: Biomarkers and personalized sorafenib therapy. **Liver Cancer** 3:399-404, 2014 (IF=0.000).
24. 2014 Nishida N, **Kudo M**: Alteration of epigenetic profile in human hepatocellular carcinoma and its clinical implications. **Liver Cancer** 3:417-427, 2014 (IF=0.000).
25. 2014 **Kudo M**, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K, on behalf of the Liver Cancer Study Group of Japan: JSH consensus-based clinical practice guidelines for the management of hepatocellular

carcinoma: 2014 update by the Liver Cancer Study Group of Japan. **Liver Cancer** 3:458-468, 2014 (IF=0.000).

26. 2014 **Kudo M**: Emerging strategies for the management of hepatocellular carcinoma. **Digest Dis** 32:655-657, 2014 (IF=1.777).
27. 2014 Nishida N, Nishimura T, Nakai T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, **Kudo M**: Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma. **Digest Dis** 32:658-663, 2014 (IF=1.777).
28. 2014 Kono M, Inoue T, **Kudo M**, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Ueshima K, Nishida N, Murakami T: Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: Results and risk factors for local recurrence. **Digest Dis** 32:670-677, 2014 (IF=1.777).
29. 2014 Minami Y, **Kudo M**: Ultrasound fusion imaging of hepatocellular carcinoma: a review of current evidence. **Diegst Dis** 32:690-695, 2014 (IF=1.777).
30. 2014 Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, **Kudo M**: Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. **Digest Dis** 32:705-710, 2014 (IF=1.777).
31. 2014 Kitai S, **Kudo M**, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T, for the Liver Cancer Study Group of Japan: Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score, and BCLC system) in 4,649 cases from a Japanese nationwide survey. **Digest Dis** 32:717-724, 2014 (IF=1.777).

32. 2014 Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, **Kudo M**: Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma. **Digest Dis** 32:733-739, 2014 (IF=1.777).
33. 2014 Nishida N, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, **Kudo M**: Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking. **Digest Dis** 32:740-746, 2014 (IF=1.777).
34. 2014 Nishida N, **Kudo M**: Clinical features of vascular disorders associated with chronic hepatitis virus infection. **Digest Dis** 32:786-790, 2014 (IF=1.777).
35. 2014 Wu T, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, **Kudo M**, Zheng RQ: Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study. **Digest Dis** 32:791-799, 2014 (IF=1.777).
36. 2014 **Kudo M**: Breakthroughs in the management of hepatocellular carcinoma: celebrating 50 years of the Liver Cancer Study Group of Japan. **Oncology** 87:1-6, 2014 (IF=2.152).
37. 2014 **Kudo M**, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, on behalf of the Liver Cancer Study Group of Japan: Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. **Oncology** 87:7-21, 2014 (IF=2.152).
38. 2014 **Kudo M**, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M,

Ogasawara S, Yamashita T, Minami T, on behalf of the Liver Cancer Study Group of Japan: Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.

Oncology 87:22-31, 2014 (IF=2.152).

39. 2014 Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, **Kudo M**: Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by LCSGJ. **Oncology** 87:32-36, 2014 (IF=2.152).
40. 2014 Kondo F, Fukusato T, **Kudo M**: Pathological diagnosis of benign hepatocellular nodular lesions based on the new world health organization classification. **Oncology** 87:37-49, 2014 (IF=2.152).
41. 2014 Ogawa C, Minami Y, Morioka Y, Noda A, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki N, Shibata M, **Kudo M**: Virtual sonography for novice sonographer: usefulness of synapse vincent^R with pre-check imaging of tumor location. **Oncology** 87:50-54, 2014 (IF=2.152).
42. 2014 Minami T, Minami Y, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Inoue T, Hagiwara S, Ueshima K, Nishida N, **Kudo M**: Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging. **Oncology** 87:55-62, 2014 (IF=2.152).
43. 2014 Yada N, **Kudo M**, Kawada N, Sato S, Osaki Y, Ishikawa A, Miyoshi H, Sakamoto M, Kage M, Nakashima O, Tonomura A: Noninvasive diagnosis of liver fibrosis: utility of data mining of both ultrasound elastography and serological findings to construct a decision tree. **Oncology** 87:63-72, 2014 (IF=2.152).
44. 2014 Ikeda K, Osaki Y, Nakanishi H, Nasu A, Kawamura Y, Jyoko K, Sano T, Sunakozaka H, Uchino Y, Minami Y, Saito Y, Nagai K,

Inokuchi R, Kokubu S, **Kudo M**: Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. **Oncology** 87:73-77, 2014 (IF=2.152).

45. 2014 Yamakado K, **Kudo M**: Treatment strategies of Intermediate-stage hepatocellular carcinomas in Japan (Barcelona clinic liver cancer stage B). **Oncology** 87:78-81, 2014 (IF=2.152).
46. 2014 Nouso K, Kokudo N, Tanaka M, Kuromatsu R, Nishikawa H, Toyoda H, Oishi N, Kuwaki K, Kusanaga M, Sakaguchi T, Morise Z, Kitai S, **Kudo M**: Treatment of hepatocellular carcinoma with Child-Pugh C cirrhosis. **Oncology** 87:99-103, 2014 (IF=2.152).
47. 2014 Tanaka K, Shimada M, **Kudo M**: Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th annual meeting of the Liver Cancer Study Group of Japan. **Oncology** 87:104-109, 2014 (IF=2.152).
48. 2014 Takita M, Hagiwara S, **Kudo M**, Kono M, Chishina H, Arizumi T, Kitai S, Yada N, Inoue T, Minami Y, Ueshima K: Efficacy and safety of Telaprevir-based antiviral treatment for elderly patients with hepatitis C virus. **Oncology** 87:110-117, 2014 (IF=2.152).
49. 2014 Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Inoue T, Hagiwara S, Ueshima K, Nishida N, **Kudo M**: Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C. **Oncology** 87:118-123, 2014 (IF=2.152).
50. 2014 **Kudo M**, Han G, Finn RS, Poon RTP, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Cruz CD, poulat V, Wang JH: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase 3 trial. **Hepatology** 60:1697-1707, 2014 (IF=11.711).

51. 2014 Ashida R, Yasukawa S, Yanagisawa A, Kamata K, **Kudo M**, Ogura T, Higuchi K, Fukutake N, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Kitano M: Prospective Multicenter Randomized Controlled Trial of Histological Diagnostic Yield Comparing 25G EUS-FNA Needles With and Without a Core Trap in Patients With Solid Pancreatic Masses. **Gastrointest Endosc**, 79:AB111, 2014 (IF=6.217).
52. 2014 Pinato DJ, Karamanacos G, Arizumi T, Adjogatse D, Kim YW, **Kudo M**, Jang JW, Sharma R: Dynamic changes of the inflammation based index (IBI) predict mortality following chemoembolization for hepatocellular carcinoma: a prospective study. **Aliment Pharm Ther** 40:1270-1281, 2014 (IF=6.320).
53. 2014 Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J, **Kudo M**: Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer. **Cancer Res** 74:6119-6128, 2014 (IF=8.556).
54. 2014 Watanabe T, Asano N, Meng G, Yamashita K, Arai Y, Sakurai T, **Kudo M**, Fuss IJ, Kitani A, Shimosegawa T, Chiba T, Strober W: NOD2 Down-regulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6. **Mucosal Immunol** 7:1312-1325, 2014 (IF=6.103).
55. 2014 Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, **Kudo M**: Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. **J Gastroenterol** 49:1578-1587, 2014 (IF=4.414).
56. 2014 Taki H, Taki K, Yamakawa M, Shiina T, **Kudo M**, Sato T: Stabilization technique for real-time high-resolution vascular ultrasound using frequency domain interferometry. **Conf Proc**

IEEE Eng Med Biol Soc 5085-5088, 2014 (IF=0.000).